Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 4 (2007), Issue 4 (April)

1. Natural history of the visual impairment of relapsing neuromyelitis optica.
   Ophthalmology, 114(4): 810-5. [Abstract] [Full-text]
2. Intrathecal antibody production in an animal model of multiple sclerosis.
   J Neuroimmunol, 185(1): 57-63. [Abstract] [Full-text]
3. Immunomodulatory properties of increased levels of liver X receptor beta in peripheral blood mononuclear cells from multiple sclerosis patients.
   Exp Neurol, 204(2): 759-66. [Abstract] [Full-text]
4. Multiple sclerosis and anti-Plasmodium falciparum innate immune response.
   J Neuroimmunol, 185(1): 201-7. [Abstract] [Full-text]
5. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.
   J Neuroimmunol, 185(1): 168-74. [Abstract] [Full-text]
6. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis.
   J Neuroimmunol, 185(1): 123-9. [Abstract] [Full-text]
7. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
   Mol Cell Neurosci, 34(4): 551-61. [Abstract] [Full-text]
8. The neuropsychiatry of multiple sclerosis: a review of recent developments.
   Curr Opin Psychiatry, 20(3): 278-85. [Abstract] [Full-text]
9. Lupoid sclerosis: what is the role of antiphospholipid antibodies?
   J Clin Rheumatol, 13(2): 85-6. [Abstract] [Full-text]
10. The blood-brain barrier in cortical multiple sclerosis lesions.
    J Neuropathol Exp Neurol, 66(4): 321-8. [Abstract] [Full-text]
11. Statistical issues related to the use of MRI data in multiple sclerosis.
    J Neuroimaging, 17: 56S-59S. [Abstract] [Full-text]
12. MRI to monitor treatment efficacy in multiple sclerosis.
    J Neuroimaging, 17: 50S-55S. [Abstract] [Full-text]
13. MRI of spinal cord in multiple sclerosis.
    J Neuroimaging, 17: 46S-49S. [Abstract] [Full-text]
14. Optic nerve imaging in multiple sclerosis.
    J Neuroimaging, 17: 42S-45S. [Abstract] [Full-text]
15. Functional MRI in multiple sclerosis.
    J Neuroimaging, 17: 36S-41S. [Abstract] [Full-text]
16. MR spectroscopy in multiple sclerosis.
    J Neuroimaging, 17: 31S-35S. [Abstract] [Full-text]
17. Diffusion tensor MRI in multiple sclerosis.
    J Neuroimaging, 17: 27S-30S. [Abstract] [Full-text]
18. Magnetization transfer MRI in multiple sclerosis.
    J Neuroimaging, 17: 22S-26S. [Abstract] [Full-text]
19. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis.
    J Neuroimaging, 17: 16S-21S. [Abstract] [Full-text]
20. Measuring brain atrophy in multiple sclerosis.
    J Neuroimaging, 17: 10S-15S. [Abstract] [Full-text]
21. Conventional MRI in multiple sclerosis.
    J Neuroimaging, 17: 3S-9S. [Abstract] [Full-text]
22. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
    Immunology, 121(1): 29-39. [Abstract] [Full-text]
23. The cost of multiple sclerosis in Australia.
    J Clin Neurosci, 14(6): 532-9. [Abstract] [Full-text]
24. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
    Lancet Neurol, 6(5): 431-41. [Abstract] [Full-text]
25. Challenges in the classification of pediatric multiple sclerosis and future directions.
    Neurology, 68(16): S70-4. [Abstract] [Full-text]
26. Consensus definitions proposed for pediatric multiple sclerosis and related disorders.
    Neurology, 68(16): S7-12. [Abstract] [Full-text]
27. The psychosocial consequences of pediatric multiple sclerosis.
    Neurology, 68(16): S66-9. [Abstract] [Full-text]
28. Treatment of pediatric multiple sclerosis and variants.
    Neurology, 68(16): S54-65. [Abstract] [Full-text]
29. MRI features of pediatric multiple sclerosis.
    Neurology, 68(16): S46-53. [Abstract] [Full-text]
30. Clinical features of children and adolescents with multiple sclerosis.
    Neurology, 68(16): S37-45. [Abstract] [Full-text]
31. Pediatric multiple sclerosis: a short history of a long story.
    Neurology, 68(16): S3-6. [Abstract] [Full-text]
32. Differential diagnosis and evaluation in pediatric multiple sclerosis.
    Neurology, 68(16): S13-22. [Abstract] [Full-text]
33. Steroid-responsive neurologic relapses in a child with a proteolipid protein-1 mutation.
    Neurology, 68(16): 1305-7. [Abstract] [Full-text]
34. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
    Neurology, 68(16): 1299-304. [Abstract] [Full-text]
35. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
    Brain, 130: 1089-104. [Abstract] [Full-text]
36. Glutathione-S-transferase T1 and M1 gene polymorphisms in Greek patients with multiple sclerosis: a pilot study.
    Eur J Neurol, 14(5): 572-4. [Abstract] [Full-text]
37. High prevalence of restless legs syndrome in multiple sclerosis.
    Eur J Neurol, 14(5): 534-9. [Abstract] [Full-text]
38. Plasma lipid peroxidation and progression of disability in multiple sclerosis.
    Eur J Neurol, 14(5): 529-33. [Abstract] [Full-text]
39. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy.
    J Neurol Sci, 256(1): 30-4. [Abstract] [Full-text]
40. Long-term prognosis of multiple sclerosis in Australia.
    J Neurol Sci, 256(1): 35-8. [Abstract] [Full-text]
41. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses.
    J Immunol Methods, 322(1): 1-11. [Abstract] [Full-text]
42. The costs and consequences of multiple sclerosis relapses: a managed care perspective.
    J Neurol Sci, 256: S39-44. [Abstract] [Full-text]
43. Control of multiple sclerosis relapses with immunomodulating agents.
    J Neurol Sci, 256: S23-8. [Abstract] [Full-text]
44. The psychosocial effect of multiple sclerosis: the impact of relapses.
    J Neurol Sci, 256: S34-8. [Abstract] [Full-text]
45. The emotional and psychological impact of multiple sclerosis relapses.
    J Neurol Sci, 256: S29-33. [Abstract] [Full-text]
46. MRI relapses have significant pathologic and clinical implications in multiple sclerosis.
    J Neurol Sci, 256: S19-22. [Abstract] [Full-text]
47. The natural history of relapses in multiple sclerosis.
    J Neurol Sci, 256: S5-13. [Abstract] [Full-text]
48. The incomplete nature of multiple sclerosis relapse resolution.
    J Neurol Sci, 256: S14-8. [Abstract] [Full-text]
49. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination.
    Brain, 130: 1105-10. [Abstract] [Full-text]
50. Down's syndrome and neuromyelitis optica (Devic's disease). An autopsy-proven case.
    Mult Scler, 13(3): 433-6. [Abstract] [Full-text]
51. Subtle upper limb impairment in asymptomatic multiple sclerosis subjects.
    Mult Scler, 13(3): 428-32. [Abstract] [Full-text]
52. Arg113His mutation of vanishing white matter is not present in multiple sclerosis.
    Mult Scler, 13(3): 424-7. [Abstract] [Full-text]
53. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals.
    Mult Scler, 13(3): 420-3. [Abstract] [Full-text]
54. Caregiver quality of life in multiple sclerosis: a multicentre Italian study.
    Mult Scler, 13(3): 412-9. [Abstract] [Full-text]
55. The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study.
    Mult Scler, 13(3): 402-11. [Abstract] [Full-text]
56. Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis.
    Mult Scler, 13(3): 393-401. [Abstract] [Full-text]
57. Health-related quality of life in secondary progressive multiple sclerosis.
    Mult Scler, 13(3): 386-92. [Abstract] [Full-text]
58. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial.
    Mult Scler, 13(3): 376-85. [Abstract] [Full-text]
59. Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation.
    Mult Scler, 13(3): 369-75. [Abstract] [Full-text]
60. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Mult Scler, 13(3): 357-68. [Abstract] [Full-text]
61. Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study.
    Mult Scler, 13(3): 348-56. [Abstract] [Full-text]
62. An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis.
    Mult Scler, 13(3): 343-7. [Abstract] [Full-text]
63. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    Mult Scler, 13(3): 336-42. [Abstract] [Full-text]
64. Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands.
    Mult Scler, 13(3): 332-5. [Abstract] [Full-text]
65. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Mult Scler, 13(3): 313-31. [Abstract] [Full-text]
66. Reduced raft-association of NF155 in active MS-lesions is accompanied by the disruption of the paranodal junction.
    Glia, 55(8): 885-95. [Abstract] [Full-text]
67. Multidisciplinary rehabilitation for adults with multiple sclerosis.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
68. Multislice brain myelin water fractions at 3T in multiple sclerosis.
    J Neuroimaging, 17(2): 156-63. [Abstract] [Full-text]
69. Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS.
    J Int Neuropsychol Soc, 13(3): 544-8. [Abstract] [Full-text]
70. Information processing deficits in multiple sclerosis: a matter of complexity.
    J Int Neuropsychol Soc, 13(3): 417-23. [Abstract] [Full-text]
71. Prospective memory in multiple sclerosis.
    J Int Neuropsychol Soc, 13(3): 410-6. [Abstract] [Full-text]
72. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis.
    Scand J Immunol, 65(5): 461-6. [Abstract] [Full-text]
73. Neuromyelitis optica following CMV primo-infection.
    J Intern Med, 261(5): 500-3. [Abstract] [Full-text]
74. Integrated care for MS patients.
    Disabil Rehabil, 29(7): 597-603. [Abstract] [Full-text]
75. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
    Neurology, 68(17): 1390-401. [Abstract] [Full-text]
76. Expiratory muscle strength training: speech production outcomes in patients with multiple sclerosis.
    Neurorehabil Neural Repair, 21(3): 239-49. [Abstract] [Full-text]
77. Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality.
    Neurorehabil Neural Repair, 21(3): 273-8. [Abstract] [Full-text]
78. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
    PLoS Med, 4(4): e133. [Abstract] [Full-text]
79. Analysis of NAMCS data for multiple sclerosis, 1998-2004.
    BMC Med, 5: 6. [Abstract] [Full-text]
80. Mental health problems in children of somatically ill parents, e.g. multiple sclerosis.
    Eur Child Adolesc Psychiatry, 16(3): 199-207. [Abstract] [Full-text]
81. Compensatory activations in patients with multiple sclerosis during preserved performance on the auditory N-back task.
    Hum Brain Mapp, 28(5): 424-30. [Abstract] [Full-text]
82. The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis.
    Hum Immunol, 68(5): 422-5. [Abstract] [Full-text]
83. HLA-DR15 haplotype and multiple sclerosis: a HuGE review.
    Am J Epidemiol, 165(10): 1097-109. [Abstract] [Full-text]
84. Segmentation of gadolinium-enhanced lesions on MRI in multiple sclerosis.
    J Magn Reson Imaging, 25(5): 932-7. [Abstract] [Full-text]
85. Environmental risk factors for multiple sclerosis. Part I: the role of infection.
    Ann Neurol, 61(4): 288-99. [Abstract] [Full-text]
86. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Ann Neurol, 61(4): 300-6. [Abstract] [Full-text]
87. 24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis.
    J Neurosci Res, 85(7): 1499-505. [Abstract] [Full-text]
88. Regulation of the syncytin-1 promoter in human astrocytes by multiple sclerosis-related cytokines.
    Virology, 362(1): 120-30. [Abstract] [Full-text]

© 2004-2008 Multiple Sclerosis Research Today. All Rights Reserved.